Background
Oncolytic virotherapy represents a promising anticancer strategy by combining direct tumor lysis with in situ immune activation. However, its efficacy remains limited in immune-cold tumors, which are characterized by poor T-cell infiltratio…
Background
Chimeric antigen receptor (CAR) T-cell therapy has demonstrated safety and modest efficacy against diffuse midline gliomas (DMGs), a highly aggressive pediatric brain tumor. However, mechanisms of CAR T-cell resistance in DMG settings remai…
Background
OX40, a key co-stimulatory receptor that amplifies T cell-mediated anti-tumor immunity, is a promising immunotherapeutic target. Despite most reported OX40 agonists in clinical trials having high affinity, the relationship between affinity …
Background
Combination immunotherapies such as atezolizumab plus bevacizumab (Atez/Bev) and durvalumab plus tremelimumab (Dur/Tre) improve outcomes in advanced hepatocellular carcinoma (HCC), yet systemic immune mechanisms underlying response remain i…
While cancer immunotherapy has traditionally centered on T cells, accumulating evidence highlights the dual roles of tumor-infiltrating B lymphocytes (TIL-Bs) in both promoting and restraining tumor progression. Within tertiary lymphoid structures (TL…
Background
Immune checkpoint inhibitors (ICIs) have been successful in treating advanced melanoma, yet, the 10-year melanoma-specific survival is only 52%. Our prior work using genetic linkage analysis revealed that the murine prolactin (PRL) locus as…
Background
Checkpoint inhibitor-induced liver injury (ChILI) is an immune-related adverse reaction, occurring in patients with cancer receiving immune checkpoint inhibitors (CPI). ChILI is currently managed with high doses of corticosteroids which car…
Background
The liver’s inherently immunosuppressive microenvironment presents a major barrier to effective immunotherapy for hepatocellular carcinoma (HCC). Although interleukin-10 (IL-10) has demonstrated antitumor activity in several cancer mo…
Background
Chimeric antigen receptor T-cell (CAR-T) therapy represents a promising frontier in oncology, but its application to high-grade gliomas (HGG) is challenged by the blood-brain barrier, limited efficacy, and significant toxicities associated …
Background
CD8 T cells mediate the effects of cancer immunotherapies. CD8 positron emission tomography (PET) imaging with [89Zr]Zr-berdoxam-crefmirlimab enables whole body CD8 cell assessment and has been shown to be safe in Phase I evaluation. The co…
